{
    "nct_id": "NCT03150810",
    "official_title": "A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "1. Age ≥18 years old with advanced or metastatic stage solid tumors\n2. Eastern Cooperative Oncology Group (ECOG) status ≤ 1\n3. Have disease either evaluable (dose-escalation cohort) or measurable (dose-escalation and -expansion cohorts) per RECIST V1.1, except for prostate cancer participants\n4. Agree to provide archival tumor tissue\n5. Additional inclusion criteria for dose expansion cohorts:\n\n   * Participants with homologous recombination deficiency (HRD+) or known BRCA mutant ovarian cancer Previously received at least one line of platinum-containing therapy in the advanced or metastatic setting and No progression or recurrent disease within 6 months from last platinum-containing regimen.\n   * Participants with HRD+ or known BRCA mutant triple-negative breast cancer Up to one prior platinum-containing treatment in any treatment setting and up to 3 prior lines of therapy in the advanced or metastatic setting\n   * Participants with HRD+ or known BRCA mutant prostate cancer Chemotherapy-naïve or previously received up to two taxane-based chemotherapy regimens, with documented prostate cancer progression\n   * Participants with small cell lung cancer and gastric cancer, previously received ≤ 2 prior lines of therapy\n   * Other HRD+ solid tumors of multiple indications\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "All participants\n\n1. Prior treatment with a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor.\n2. Refractory to platinum-based therapy (dose-expansion cohort).\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}